Table 5.
Plasma D‐ and L‐serine and change from baseline (µg/ml).
|
Placebo n = 27 |
Luvadaxistat 75 mg BID n = 14 |
Luvadaxistat 300 mg BID n = 26 |
|
|---|---|---|---|
| Plasma l‐serine (µg/ml) | |||
| Baseline, observed mean (SD) | 10.5 (2.99) | 10.5 (3.31) | 11.5 (3.53) |
| Final/week 12 change from baseline | |||
| Patients, n | 24 | 12 | 24 |
| Mean (SD) | 0.464 (1.982) | 0.817 (2.851) | 0.150 (2.274) |
|
LS mean difference (SE), luvadaxistat versus placebo |
0.184 (0.696) | −0.114 (0.574) | |
| Plasma d‐serine (µg/ml) | |||
| Baseline, observed mean (SD) | 0.142 (0.0360) | 0.144 (0.0283) | 0.157 (0.0460) |
| Final/week 12 change from baseline | |||
| Patients, n | 24 | 12 | 24 |
| Mean (SD) | 0.00383 (0.02874) | 0.0656 (0.0340) | 0.0625 (0.0514) |
|
LS mean difference (SE), luvadaxistat versus placebo |
0.0591 (0.0136) 1 | 0.0554 (0.0113) 1 | |
| Ratio of d‐serine to total serine | |||
| Baseline, observed mean (SD) | 0.0138 (0.00358) | 0.0144 (0.00433) | 0.0141 (0.00484) |
| Final/week 12 change from baseline | |||
| Patients, n | 24 | 12 | 24 |
| Mean (SD) | −0.0004 (0.00234) | 0.0048 (0.00333) | 0.0052 (0.00447) |
|
LS mean difference (SE), luvadaxistat versus placebo |
0.0052 (0.00121) 1 | 0.0059 (0.00100) 1 | |
BID, twice daily; LS, least squares; SD, standard deviation; SE, standard error.
1
Two‐sided p value < 0.001.